Induction immunosuppression with antithymocyte globulin in renal transplantation using a variable dose according to the absolute number of CD3+ T cells.
D000328:Adult; D015703:Antigens, CD / Q000097:blood*; D000961:Antilymphocyte Serum / Q000191:economics / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology; D017252:CD3 Complex / Q000097:blood*; D003365:Costs and Cost Analysis; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000628:therapy; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation / Q000191:economics / Q000276:immunology* / Q000401:mortality; D016853:Muromonab-CD3 / Q000627:therapeutic use; D015996:Survival Rate; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D013997:Time Factors
D015703:Antigens, CD; D000961:Antilymphocyte Serum; D017252:CD3 Complex; D016853:Muromonab-CD3